Instructions for Plaquenil (hydroxychloroquine)
English Product Name
Plaquenil®
Release Form hydroxychloroquine
Coated tablets
Description Plaquenil
White coated tablets are round, biconvex, engraved "HCQ" on one side and "200" on the other.
1 tab
hydroxychloroquine sulfate 200 mg
Auxiliary substances: lactose monohydrate, povidone K25, corn starch, magnesium stearate, opadrae OY-L-28900 (hypromellose, macrogol 4000, titanium dioxide (E171), lactose monohydrate).
10 pcs - blisters (6) - cardboard packs.
ATX codes
P01BA02 Hydroxychloroquine
Clinical and pharmacological groups / Group affiliation
A derivative of 4-aminoquinoline. An anti-malarial and amebicide drug. Immunosuppressant
Active ingredient
hydroxychloroquine sulfate
Pharmacotherapeutic group Plaquenil
Antimalarial
Expiration date
Shelf life is 3 years.
Pharmacological effect Plaquenil
Plaquenil exhibits anti-malarial properties and has anti-inflammatory and immunosuppressive effects in chronic discoid and systemic lupus erythematosus (SLE) as well as acute and chronic rheumatoid arthritis. The drug's mechanism of action in malaria, SLE, and rheumatoid arthritis is not fully understood.
Hydroxychloroquine acts as a mild immunosuppressant, inhibiting synthesis of rheumatoid factor and elements of the acute inflammatory response. It accumulates in white blood cells, helping to stabilize lysosomal membranes and suppressing the activity of various enzymes, such as collagenase and protease, which cause cartilage to break down.
The efficacy of this agent in SLE and rheumatoid arthritis is due to the following anti-inflammatory and immunomodulatory properties of hydroxychloroquine:
Increasing intracellular pH, which slows antigen response and reduces peptide binding to major histocompatibility complex (MHC) receptors
Suppression of phospholipase A2 activity
Decrease levels of cytokines IL-1 and IL-6, which diminishes the clinical manifestations of the autoimmune response
Inhibition of DNA and RNA transcription processes.
It is effective against the asexual RBC forms and gametes Plasmodium vivax and Plasmodium malariae but has no effect on gametes Plasmodium falciparum and is not active against resistant strains or non-RBC forms of other species.
Indications for use Plaquenil:
- Rheumatoid arthritis
- Juvenile rheumatoid arthritis
- Systemic lupus erythematosis
- discoid lupus erythematosus.
- Malaria (excluding chloroquine-resistant Plasmodium falciparum strains):
- Prevent and treat acute malaria due to Plasmodium vivax, Plasmodium ovale, and Plasmodium malariae and susceptible Plasmodium falciparum strains;
- for definitive treatment of malaria caused by sensitive strains of Plasmodium falciparum.
Method of use, course and dosage Plaquenil
Plaquenil is intended for oral use only. The drug is taken with food or with a glass of milk.
All doses are based on hydroxychloroquine sulfate and are not equivalent to those of the base.
Treatment of Rheumatoid Arthritis
Hydroxychloroquine has cumulative activity. Its therapeutic effect requires several weeks of treatment, while side effects can occur relatively early. The necessary therapeutic effect develops after several months of administration of the drug. If patients do not improve objectively within 6 months of taking hydroxychloroquine, the drug should be stopped.
- Nosology hydroxychloroquine (ICD codes)
- B50
- Plasmodium falciparum malaria
- B51
- Plasmodium vivax malaria
- B52
- Plasmodium malariae malaria
- L93.0
- Discoid lupus erythematosus
- M05
- Seropositive rheumatoid arthritis
- M08
- Juvenile [juvenile] arthritis
- M32
- Lupus erythematosus systemic
